Kronos Bio Inc (NAS:KRON)
$ 1.01 0 (0%) Market Cap: 60.70 Mil Enterprise Value: -60.21 Mil PE Ratio: 0 PB Ratio: 0.44 GF Score: 32/100

Kronos Bio Inc at Piper Sandler Healthcare Conference Transcript

Nov 29, 2022 / 04:30PM GMT
Release Date Price: $1.75 (-2.23%)
Ted Tenthoff
Piper Sandler Companies - Analyst

Good morning. My name is Ted Tenthoff. I'm a Senior Biotech Analyst at Piper Sandler. And before I begin, I am required to point out certain disclosures regarding the relationship between Piper and our next presenting company Kronos, which are located at the back of the room and also at the registration desk.

Kronos Bio is developing small molecules that target dysregulated transcription factors and also the associated transcriptional regulation networks, or TRNs, but really with a focus on cancer.

The company is conducting a Phase 1b study of Lanraplenib for -- or what I like to call Lanra because it's little easier to pronounce -- for FLT3-mutant AML. And the company is also conducting a Phase 1/2 study of oral KB-0742 for MYC-Dependent Solid Tumors hopefully with data coming out in the next couple of weeks. The company continues to invest in several discovery programs. So stay tuned. There's going to be a lot more to focus on over the years to come.

Here with us today is Dr. Norbert Bischofberger, President and CEO, and also,

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot